AAN 2022 | Cognitive and psychiatric adverse events associated with cenobamate

Significant cognitive and behavioral adverse events are often associated with antiseizure medications. William E. Rosenfeld, MD, FAAN, The Comprehensive Epilepsy Care Center for Children and Adults, St Louis, MO, discusses a pooled analysis of the Phase II double-blind C013 (NCT01397968) and C017 (NCT01866111) studies and their open-label extensions, and the C021 Phase III open-label safety study (NCT02535091), evaluating the cognitive and psychiatric treatment-related adverse events associated with cenobamate use. During the 5-year analysis period, incidence of both cognitive and psychiatric adverse events was low. In patients with a history of psychiatric events, incidence was found to be lower than at baseline. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.